Spero Therapeutics’ (SPRO) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Spero Therapeutics (NASDAQ:SPRO)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued on Friday,Benzinga reports.

Several other equities analysts have also weighed in on the stock. HC Wainwright reduced their price target on shares of Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, November 4th. TD Cowen upgraded Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th.

Spero Therapeutics Stock Down 5.6 %

Shares of NASDAQ SPRO opened at $1.18 on Friday. The company has a market capitalization of $63.71 million, a PE ratio of 16.86 and a beta of 0.63. The stock’s 50 day moving average price is $1.29 and its 200-day moving average price is $1.36. Spero Therapeutics has a twelve month low of $1.01 and a twelve month high of $1.89.

Institutional Investors Weigh In On Spero Therapeutics

Several institutional investors have recently made changes to their positions in SPRO. Acadian Asset Management LLC raised its stake in shares of Spero Therapeutics by 121.8% during the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after purchasing an additional 418,742 shares during the period. Renaissance Technologies LLC grew its stake in Spero Therapeutics by 14.2% during the second quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock valued at $1,269,000 after acquiring an additional 121,492 shares in the last quarter. Virtu Financial LLC purchased a new stake in Spero Therapeutics in the 1st quarter worth approximately $31,000. Murchinson Ltd. lifted its stake in Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after purchasing an additional 11,210 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Spero Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after purchasing an additional 9,675 shares during the period. Hedge funds and other institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.